Active Components of Ligusticum chuanxiong and Related Preparations in Prevention and Treatment of Atherosclerosis： A Review
10.13422/j.cnki.syfjx.20251637
- VernacularTitle:川芎活性成分及相关制剂防治动脉粥样硬化的研究进展
- Author:
Lijia SONG
1
;
Shuai WANG
2
;
Wenrui LU
1
;
Yunfeng XIA
1
;
Fengrong WANG
2
Author Information
1. Graduate School of Liaoning University of Traditional Chinese Medicine （TCM）， Shenyang 110847， China
2. Affiliated Hospital of Liaoning University of TCM， Shenyang 110032， China
- Publication Type:Journal Article
- Keywords:
atherosclerosis;
anti-atherosclerotic mechanism;
Ligusticum chuanxiong and its active ingredients;
Ligusticum chuanxiong herb pair;
Chinese medicine compound formulas containing Ligusticum chuanxiong
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(6):297-306
- CountryChina
- Language:Chinese
-
Abstract:
Atherosclerosis （AS） is a vascular disease primarily affecting large and medium-sized arteries. It serves as the pathological basis for many cardiovascular and cerebrovascular diseases and is associated with a relatively high incidence of complications and mortality worldwide. Traditional Chinese medicine （TCM） plays an important role in the prevention and treatment of AS， demonstrating unique therapeutic advantages through multiple targets and pathways. Ligusticum chuanxiong， a commonly used Chinese medicine in clinical practice， contains key active components against AS， including ligustrazine， senkyunolide， ligustilide， quercetin， ferulic acid， vanillic acid， chlorogenic acid， gallic acid， protocatechuic acid， caffeic acid， chrysophanol， and β-sitosterol. Recent literature indicates that these active components can regulate AS through multiple mechanisms， including improving endothelial cell dysfunction， alleviating lipid metabolism disorders， inhibiting macrophage foam cell formation， suppressing the invasion， proliferation， and migration of smooth muscle cells， inhibiting apoptosis， exerting anticoagulant effects and inhibiting platelet activation， protecting mitochondrial function， and modulating intestinal flora and its metabolites， demonstrating significant pharmacological activity and clinical potential. Clinically， L. chuanxiong is often combined with Salvia miltiorrhiza， Paeonia lactiflora， Angelica sinensis， and borneol to form compound formulations， enhancing therapeutic effects and achieving synergistic anti-AS activity. Compound treatment with L. chuanxiong primarily focuses on promoting blood circulation and shows significant efficacy for different AS syndrome types. This article provides an in-depth review of the active components， drug pairs， and compound preparations of L. chuanxiong in the prevention and treatment of AS， aiming to lay a foundation for subsequent theoretical research and clinical applications in managing AS and its related complications.
